| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body’s natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents. (en)
|
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...drugbank/halfLife
| |
| http://linked.open...ugbank/indication
| - Ambroxol is indicated as “secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply. (en)
|
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Ambroxol is a mucolytic agent. Excessive Nitric oxide (NO) is associated with inflammatory and some other disturbances of airways function. NO enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. It is also possible that the inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion, therefore it lowers the phlegm viscosity and improves the mucociliary transport of bronchial secretions. (en)
|
| http://linked.open.../drugbank/synonym
| - Ambroxol (en)
- 4-(((2-Amino-3,5-dibromophenyl)methyl)amino)cyclohexanol (en)
- Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)-, trans- (en)
- trans-4-((2-Amino-3,5-dibromobencil)amino)ciclohexanol (en)
- 4-(2-Amino-3,5-dibromo-benzylamino)-cyclohexanol (en)
- 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol (en)
- N-(2-Amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanol (en)
- Amboxol (en)
- Ambroxol hcl (en)
- Ambroxolum (en)
- Bisolvon metabolite vIII (en)
- Bromhexine metabolite vIII (en)
- Bromhexine-metabolite vIII (en)
- SID29215331 (en)
- SID50085991 (en)
- Tabcin (en)
- Tabcin (TN) (en)
- trans-4-((2-Amino-3,5-dibromobenzyl)amine)cyclohexanol (en)
- trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol (en)
- Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (E)- (en)
- N-(2-Amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol (en)
|
| http://linked.open...nk/proteinBinding
| |
| http://linked.open...ogy/drugbank/salt
| |
| http://linked.open...ynthesisReference
| - Kack, J., Koss, F.W., Schraven, E. and Beisenherz, G.; US. Patent 3,536,713; October 27, 1970; assigned to Boehringer lngelheim G.m.b.H. (en)
|
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...ugbank/absorption
| - Rapid and almost complete. (en)
|
| http://linked.open...casRegistryNumber
| |
| http://linked.open...drugbank/category
| |
| http://linked.open...ank/Melting-Point
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)